What is wave genetics?
Wave genetics is an emerging theory that proposes that our DNA communicates through electromagnetic waves to influence gene expression. Although not widely accepted by scientists, research is underway to further examine its ramifications – including an apparent “illusory force” between people when holding hands without touching. This phenomenon could account for why “illusionary forces” exist between two people when holding their hands together without touching.
Gariaev’s groundbreaking research suggests that DNA could also function like waves – electromagnetic waves carrying genetic information could quickly travel over long distances to change gene expression instantly and instantly. His groundbreaking theory provides ample proof that these electromagnetic waves exist! This revolutionary notion was proven by Gariaev’s work.
Wave genetics has many applications. For instance, it could help cure genetic diseases or extend life spans; however, any manipulation of DNA’s wave patterns could have unintended repercussions, making it essential to first fully comprehend its complex wave and holographic properties before engaging in genetic modification efforts.
Wave genetics research indicates that our DNA is far more intricate than originally assumed. Researchers have recently revealed that it consists not only of single chromosomes but is instead composed of an abundance of microRNAs (miRNAs) and other small molecules, all working in concert to control gene expression in highly dynamic ways.
Wave genetics holds immense promise to revolutionize medicine, extend human lives and decode genetic codes. But as with any powerful technology, its deployment requires responsible innovation and ethical considerations to ensure its benefits can be balanced by mitigating risks. Wave Life Sciences and GSK have joined forces to advance the development of oligonucleotide therapeutics, specifically targeting alpha-1 antitrypsin deficiency (AATD), through WVE-006. Under the terms of their four-year research collaboration agreement, GSK will be responsible for discovering and global developing Wave’s RNA Editing Platform as well as preclinical programs. Meanwhile, Wave will use their PRISM platform to discover new medicines.
